Teriparatide (Forteo): The First Bone-Building Osteoporosis Drug

Most osteoporosis drugs work by slowing down the loss of bone. Bisphosphonates, denosumab, and similar antiresorptive agents put the brakes on the cells that break bone down. Teriparatide did something different, and when the U.S. Food and Drug Administration approved it in November 2002, it became the first anabolic osteoporosis therapy on the market: a drug that actively stimulates the body to build new bone rather than merely preserving what is there.

This entry logs what teriparatide is, the trial that established it, the counterintuitive biology behind it, and how its regulatory label has changed over two decades. It is a reference summary, not medical advice.

What teriparatide actually is

Teriparatide is recombinant human parathyroid hormone, specifically the first 34 amino acids of the 84-amino-acid PTH molecule — hence the shorthand PTH(1-34). That fragment retains the biologically active portion of the hormone. It is produced by recombinant DNA technology and was developed by Eli Lilly, marketed as Forteo. It is given as a once-daily subcutaneous injection. You can find a structured entry in our teriparatide peptide reference.

The paradox: the same hormone builds or breaks bone

Parathyroid hormone has a reputation as a bone destroyer. In hyperparathyroidism — where the parathyroid glands oversecrete PTH continuously — the net effect is bone resorption, and the skeleton loses density. So how can a PTH fragment be a bone builder?

The answer is timing. The skeletal response to PTH depends on the pattern of exposure. Sustained, continuous exposure to PTH tips the balance toward resorption (the catabolic effect seen in hyperparathyroidism). But brief, intermittent exposure — a single small daily injection that spikes and clears — activates bone-forming osteoblasts more than bone-resorbing osteoclasts, producing a net anabolic effect. Researchers describe an early "anabolic window": bone-formation markers rise first, while resorption markers climb later, so the window in which formation outpaces resorption is widest early in treatment and narrows over time. The precise molecular reasons for this catabolic-versus-anabolic split are still not fully worked out, but the phenomenon itself is well established and is the entire rationale for once-daily dosing.

The evidence: the Fracture Prevention Trial

The pivotal trial behind teriparatide's approval was the Fracture Prevention Trial, reported by Neer and colleagues in the New England Journal of Medicine in 2001. It was a randomized, placebo-controlled study of 1,637 postmenopausal women who each had at least one prior vertebral fracture — a group at high risk of further fractures.

Over a median follow-up of roughly 21 months, women receiving 20 micrograms of teriparatide daily had:

Those are meaningful reductions in the outcome that matters clinically — actual fractures, not just density readouts — and they are why teriparatide was approved with strong data behind it. Later work also supported use in men: in male osteoporosis, daily teriparatide over a median of about 11 months increased lumbar-spine BMD by roughly 5.9% versus placebo, informing the initial 2002 label.

The osteosarcoma warning — and its removal

From its 2002 approval, teriparatide carried a boxed warning for osteosarcoma, a bone cancer. The signal came from preclinical toxicology: in Fischer 344 rats given high doses for a near-lifetime exposure, osteosarcoma developed in a substantial fraction of animals. Out of caution, the original label also capped cumulative use at 24 months during a patient's lifetime.

That rat finding never translated into the human data. Over years of postmarketing use, large observational studies linked pharmacy claims records to state cancer-registry data to look for osteosarcoma among treated patients, and found no increase compared with unexposed groups or with the expected background rate of the disease. On the strength of that real-world evidence, the FDA updated the label in November 2020: the boxed warning was removed, osteosarcoma language was moved into the standard Warnings and Precautions section, and the strict 2-year lifetime cap was revised. The current label instead allows clinicians to consider treatment beyond two years if a patient remains at, or returns to, high fracture risk. Regulatory status can change, so always confirm the current label — see our FDA status tracker.

Biosimilars and follow-on products

Teriparatide is no longer a single-source drug. In October 2019, the FDA approved Pfenex's follow-on teriparatide product (PF708, later marketed as Bonsity) — notably via the 505(b)(2) pathway rather than the formal biosimilar route — and additional teriparatide products have followed, broadening access to the molecule.

Where it sits among anabolic agents

Teriparatide was first, but it is no longer alone in the bone-building category. Abaloparatide, an analog of PTH-related protein rather than PTH itself, was later developed as another anabolic option and is often discussed as teriparatide's closest comparator; see our abaloparatide entry for how the two differ. Anabolic agents are generally reserved for higher-risk patients and are frequently followed by an antiresorptive drug to hold onto the gains, since bone density tends to decline again after stopping.

Teriparatide's record is a useful example of evidence maturing over time: approved on strong fracture-outcome data, shadowed for years by a rodent safety signal, and eventually reassessed as human data accumulated. The honest summary is that it is an FDA-approved therapy with a solid trial foundation and a safety label that has been revised in light of real-world evidence — not a speculative compound.

PepStash is a research log and reference tool. This article is educational and is not medical advice — it does not diagnose, treat, or recommend any protocol. Regulatory status and trial data change; always verify against primary sources and consult a licensed physician before making any decisions about your health.